Ayako W. Pedersen
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Arginase-1-specific T cells target and modulate tumor-associated macrophages.
Journal: Journal for immunotherapy of cancer
Published: December 14, 2024
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Journal: Frontiers in immunology
Published: August 19, 2022
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Journal: Nature medicine
Published: March 09, 2022
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status.
Journal: Cancer immunology research
Published: June 09, 2021
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner.
Journal: Cellular & molecular immunology
Published: September 18, 2020
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Journal: Oncoimmunology
Published: September 14, 2020
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.
Journal: Journal for immunotherapy of cancer
Published: June 01, 2020
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.
Journal: Nature reviews. Rheumatology
Published: January 25, 2018
The RA-MAP Consortium: a working model for academia-industry collaboration.
Journal: Nature reviews. Rheumatology
Published: December 08, 2017
Immunoregulatory antigens-novel targets for cancer immunotherapy.
Journal: Chinese clinical oncology
Published: October 30, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026